Arrowhead Pharmaceuticals (ARWR) News Today $16.74 -0.23 (-1.36%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$16.74 0.00 (0.00%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARWR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period GAMMA Investing LLC Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)GAMMA Investing LLC grew its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 4,965.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,710 shares of the biotechnology company's stockJune 12 at 3:39 AM | marketbeat.comResearch Analysts Set Expectations for ARWR FY2026 EarningsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Arrowhead Pharmaceuticals in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the biotechnology company willJune 11 at 9:04 AM | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJune 10 at 1:59 AM | americanbankingnews.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of "Moderate Buy" from AnalystsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight analysts that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and six have issued a buy rating onJune 10 at 1:58 AM | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at Wall Street ZenJune 7, 2025 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded by Wall Street Zen to Buy RatingWall Street Zen upgraded Arrowhead Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday.June 7, 2025 | marketbeat.comJim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money”June 5, 2025 | msn.comJim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'June 4, 2025 | benzinga.comArrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a StudyJune 2, 2025 | insidermonkey.comSquarepoint Ops LLC Has $1.62 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Squarepoint Ops LLC reduced its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 55.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 86,044 shares of the biotechnology company's stoMay 31, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 6.2% - Should You Buy?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading 6.2% Higher - Here's What HappenedMay 30, 2025 | marketbeat.comArrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade)May 29, 2025 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Pharma Mar SA (OtherPHMMF)May 29, 2025 | theglobeandmail.comArrowhead Pharmaceuticals to Participate in June 2025 Investor ConferencesMay 29, 2025 | businesswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $37.79 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 6.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,010,129 shMay 27, 2025 | marketbeat.comNeo Ivy Capital Management Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Neo Ivy Capital Management acquired a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 16,920 shares of the biotechnology company's stock, valued at approximately $318,0May 26, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Acquired by Two Sigma Advisers LPTwo Sigma Advisers LP lifted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 330.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 430,700 sharMay 26, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Acquired by Two Sigma Investments LPTwo Sigma Investments LP boosted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 281.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 794,373 shares of the biotechnology comMay 25, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to Hold at StockNews.comStockNews.com upgraded shares of Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday.May 24, 2025 | marketbeat.comResearch Analysts Set Expectations for ARWR FY2025 EarningsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Stock analysts at HC Wainwright upped their FY2025 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a research note issued on Tuesday, May 20th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnolMay 24, 2025 | marketbeat.comWoodline Partners LP Cuts Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Woodline Partners LP reduced its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 3.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 840,174 shares of the biotechnology company's stock after sellingMay 24, 2025 | marketbeat.comMillennium Management LLC Boosts Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Millennium Management LLC lifted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 41.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 914,550 shares of the biotechnology company's stocMay 24, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday.May 22, 2025 | marketbeat.comRafferty Asset Management LLC Cuts Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Rafferty Asset Management LLC lessened its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 23.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 138,377 shares of the biMay 22, 2025 | marketbeat.comSilvercrest Asset Management Group LLC Grows Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Silvercrest Asset Management Group LLC lifted its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 24.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 280,511 shares of the biotechnology compaMay 21, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $4.56 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 15.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 242,702 shares of the bioMay 21, 2025 | marketbeat.comDeutsche Bank AG Has $4.87 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Deutsche Bank AG grew its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 17.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 258,964 shares of the biotechMay 21, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires 32,841 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)BNP Paribas Financial Markets boosted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 59.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 88,029 sMay 21, 2025 | marketbeat.comTema Etfs LLC Takes $1.16 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Tema Etfs LLC purchased a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 61,503 shares of the biotechnology company's stock, valued at apprMay 20, 2025 | marketbeat.comDimensional Fund Advisors LP Sells 86,214 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Dimensional Fund Advisors LP reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 70.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,666 shares of the biotechnology comMay 19, 2025 | marketbeat.comSphera Funds Management LTD. Purchases New Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Sphera Funds Management LTD. purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 197,550 shares of the biotechnology company's stock, valued at approximately $3,714,000.May 18, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and six haveMay 18, 2025 | marketbeat.comArrowhead Pharmaceuticals’ Earnings Call Highlights Growth and ChallengesMay 15, 2025 | tipranks.comARWR: Multiple Value Drivers for Long-Term Growth…May 15, 2025 | finance.yahoo.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up on Earnings BeatArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up on Earnings BeatMay 15, 2025 | marketbeat.comChardan Capital Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)Chardan Capital restated a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday.May 15, 2025 | marketbeat.comHudson Bay Capital Management LP Lowers Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Hudson Bay Capital Management LP reduced its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 20.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 175,000 shareMay 15, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Issues Quarterly Earnings ResultsArrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) issued its quarterly earnings results on Monday. The biotechnology company reported $2.75 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $2.81.May 14, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call TranscriptMay 14, 2025 | msn.comIntegral Health Asset Management LLC Invests $5.17 Million in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Integral Health Asset Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 275,000 shares of the biotechnology company's stockMay 14, 2025 | marketbeat.comArrowhead Shares Rise After 2Q Earnings BeatMay 13, 2025 | marketwatch.comArrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ...May 13, 2025 | finance.yahoo.comNorthern Trust Corp Has $27.91 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Northern Trust Corp increased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 11.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,484,419 shares of the biotechnology company'sMay 13, 2025 | marketbeat.comArrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter ResultsMay 13, 2025 | finance.yahoo.comArrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comBalyasny Asset Management L.P. Has $7.01 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Balyasny Asset Management L.P. lifted its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 266.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 372,749 shares of the biotechnology company's stockMay 12, 2025 | marketbeat.comFarallon Capital Management LLC Buys Shares of 628,800 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Farallon Capital Management LLC purchased a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 628,800 shares of the bMay 11, 2025 | marketbeat.comBrevan Howard Capital Management LP Raises Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Brevan Howard Capital Management LP grew its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 232.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 34,556 shares of theMay 11, 2025 | marketbeat.comRaymond James Financial Inc. Buys Shares of 34,633 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Raymond James Financial Inc. purchased a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 34,633 shareMay 10, 2025 | marketbeat.comVoya Investment Management LLC Has $1.01 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Voya Investment Management LLC trimmed its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 82.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor ownMay 9, 2025 | marketbeat.com Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Media Mentions By Week ARWR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARWR News Sentiment▼0.730.90▲Average Medical News Sentiment ARWR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARWR Articles This Week▼87▲ARWR Articles Average Week Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Blueprint Medicines News Roivant Sciences News Revolution Medicines News BridgeBio Pharma News Elanco Animal Health News Verona Pharma News Legend Biotech News TG Therapeutics News Grifols News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARWR) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARWR Stock Free ARWR Stock Alerts